Global uptake of essential cancer medicines with and without complex genomic diagnostics: a retrospective observational study.
BACKGROUND New cancer medicines increasingly depend on molecular testing, from low-cost immunohistochemistry to expensive genomic diagnostics. The WHO Model List of Essential Medicines (EML) guides access to priority medicines. We aimed to analyse uptake trends for essential cancer medicines in 71 countries and two wor...